Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome. Archives of Clinical and Medical Case Reports, v. 6, n. 5, p. 660–668, 5 Oct.2022.